Sandoz Secures EU Approval for Diabetes Biosimilars

Sandoz Group AG has received European Commission approval for two biosimilar insulins, Bysumlog (insulin lispro) and Dazparda (insulin aspart), enhancing its position in the diabetes market. Developed by Gan & Lee Pharmaceuticals, these treatments aim to broaden insulin access for diabetes patients across Europe.

Both insulins are designed for use in prefilled pens and claim to offer efficacy and safety comparable to reference medicines Humalog and NovoRapid. Following the earlier approval of Ondibta (insulin glargine), Sandoz's portfolio now further strengthens its foothold in affordable diabetes care.

Diabetes, a chronic condition affecting millions in Europe, sees increasing prevalence and healthcare costs. Sandoz's initiatives are part of a broader strategy to address this, aiming to tap into a projected USD 320 billion biosimilar market over the next decade.